Analysts predict that Corium International Inc (NASDAQ:CORI) will report earnings of ($0.43) per share for the current quarter, according to Zacks. Two analysts have made estimates for Corium International’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at ($0.40). Corium International reported earnings per share of ($0.46) in the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The company is scheduled to issue its next earnings report on Monday, February 12th.
According to Zacks, analysts expect that Corium International will report full year earnings of ($1.47) per share for the current year, with EPS estimates ranging from ($1.58) to ($1.33). For the next fiscal year, analysts expect that the business will report earnings of ($1.33) per share, with EPS estimates ranging from ($1.69) to ($0.94). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Corium International.
Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. Corium International had a negative return on equity of 482.64% and a negative net margin of 149.99%.
In other news, major shareholder Perceptive Advisors Llc acquired 50,350 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were bought at an average price of $11.83 per share, with a total value of $595,640.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $10.96, for a total value of $5,480,000.00. The disclosure for this sale can be found here. 46.50% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in CORI. Stonepine Capital Management LLC bought a new position in Corium International in the second quarter worth approximately $3,085,000. State Street Corp bought a new position in Corium International in the second quarter worth approximately $1,840,000. EAM Investors LLC bought a new position in Corium International in the second quarter worth approximately $563,000. TIAA CREF Investment Management LLC bought a new position in Corium International in the second quarter worth approximately $411,000. Finally, Bank of New York Mellon Corp grew its stake in Corium International by 161.8% in the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock worth $494,000 after purchasing an additional 40,891 shares in the last quarter. 89.08% of the stock is currently owned by institutional investors.
Shares of Corium International (CORI) traded up $0.54 during midday trading on Friday, hitting $13.63. The stock had a trading volume of 341,098 shares, compared to its average volume of 191,285. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 2.70. Corium International has a 12-month low of $2.67 and a 12-month high of $13.85. The stock has a market capitalization of $492.29, a P/E ratio of -8.16 and a beta of 1.26.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Corium International Inc (CORI) to Announce -$0.43 Earnings Per Share” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/21/zacks-brokerages-anticipate-corium-international-inc-cori-to-announce-0-43-earnings-per-share.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.